Catalyst Wire Dossier Catalyst Wire Dossier

Amikacin inhalation solution BAY41-6551

amikacin · Bayer
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Amikacin inhalation solution BAY41-6551, covering 2018-06-26 to 2018-06-26. Get the full timeline:

Most recent: Clinical Trial Update: Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia [Phase 3]

See pricing